Novo Nordisk's Innovative Portfolio and Full Pipeline in Diabetes and Obesity Supports Its Wide Moat

As a pioneer in diabetes care, Novo has been in the business for more than 85 years and claims 30% of the $50 billion-plus diabetes treatment market and roughly half of the $20 billion insulin market. The prevalence of diabetes is expected to soar in the coming decades as a result of an increasingly overweight and aging population, and we expect Novo to maintain its wide moat as it continues to dominate in diabetes and obesity therapy innovation.